Engineering For The Demands of Coronary Bypass.
ZoIvian is developing a surgeon-tailorable synthetic coronary conduit that integrates CABG-specific mechanical and handling performance with targeted biomimetic functions designed to address graft failure mechanisms.
Explore our approachConnect with ZoIvianA Proven Operation. A Persistent Conduit Challenge.
Coronary artery bypass grafting (CABG) uses a patient’s own arteries or veins to restore blood flow around blocked coronary arteries. These autologous grafts remain the standard of care, especially the left internal thoracic artery.[1]
Suitable vessels are not always available.[2] Harvesting adds tissue injury and wound-care burden,[3] and vein grafts can narrow or fail over time.[4]
ZoIvian is developing a coronary-specific synthetic conduit to expand surgeons’ graft options.
Why another conduit mattersBuilt Around The Clinical Task
We are developing a manufactured conduit for routing, trimming, and suturing in coronary artery bypass grafting, with mechanical performance and biological function integrated in one design.
Coronary-Specific Engineering
Developing mechanical behavior suited to the demands of coronary bypass.
Surgical Usability
Designing around the handling, routing, trimming, and suturing involved in CABG.
Targeted Biomimetic Function
Incorporating biological design objectives that address relevant graft failure mechanisms.
An Integrated Vision. A Staged Development Program.
Biomimetic function is central to the product concept from the outset. The evaluation plan begins with fabrication and bench testing to establish a scaffold baseline, followed by assessment of selected biological functions and their integration with structure and surgical use.
Science & DevelopmentAdvance Coronary Conduit Development With Us.
We welcome conversations with research collaborators, fabrication and testing specialists, funders, investors, and clinicians who share an interest in coronary conduit development.
Discuss a collaborationSources & References
These references support the clinical context and procedure estimates, not ZoIvian product performance.
- Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. J Am Coll Cardiol. 2022;79(2):e21–e129. Section 12.2: bypass conduits in patients undergoing CABG. Read source. Return to text
- Leonardi S, et al. Composition, structure, and function of heart teams. Joint ACVC/EAPCI/EACTS/EACTA position paper. Eur J Cardiothorac Surg. 2021;59:522–531. Conduit-selection section. Read source. Return to text
- Zenati MA, et al. Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass. N Engl J Med. 2019;380:132–141. REGROUP trial. Read source. Return to text
- Sandner S, et al. Intra-operative and post-operative management of conduits for coronary artery bypass grafting. ESC/EACTS clinical consensus statement. Eur J Cardiothorac Surg. 2024;66(6):ezae400. Read source. Return to text
- Medistim ASA. First Quarter Financial Results 2025. “Market position and outlook,” p. 9. Industry estimate of more than 700,000 cardiac bypass surgeries annually worldwide; not a worldwide registry tally. Read source. Return to text
- California HCAI. CCORP Updates (2026), slide 10. Reports 159,980 isolated CABG procedures in the 2024 STS benchmark. Isolated CABG excludes combined cardiac operations. Read source. Return to text
